Literature DB >> 10711963

Biomaterials used in the posterior segment of the eye.

M J Colthurst1, R L Williams, P S Hiscott, I Grierson.   

Abstract

The treatment of posterior segment eye disease and related conditions has improved greatly in recent years with the advent of new therapies, materials and devices. Vitreoretinal conditions, however, remain significant causes of blindness in the developed world. Biomaterials play a major role in the treatment of many of these disorders and the success rate of vitreoretinal surgery, especially in the repair of retinal detachment and related conditions, would increase with the introduction of new and improved materials. This review, which focuses on disorders that feature retinal detachment, briefly describes the anatomy of the eye and the nature and treatment of posterior segment eye disorders. The roles, required properties and suitability of the materials used in vitreoretinal surgery as scleral buckles, tamponade agents or drug delivery devices, are reviewed. Experimental approaches are discussed, along with the methods used for their evaluation, and future directions for biomaterial research in the posterior segment of the eye are considered.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10711963     DOI: 10.1016/s0142-9612(99)00220-3

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  15 in total

1.  Clinicopathological correlation of epiretinal membranes and posterior lens opacification following perfluorohexyloctane tamponade.

Authors:  P Hiscott; R M Magee; M Colthurst; N Lois; D Wong
Journal:  Br J Ophthalmol       Date:  2001-02       Impact factor: 4.638

2.  Evaluation of supporting role of a foldable capsular vitreous body with magnetic resonance imaging in the treatment of severe retinal detachment in human eyes.

Authors:  R Zhang; T Wang; C Xie; X Lin; Z Jiang; Z Wang; Y Liu; Y Luo; C Long; L He; P Wang; Q Gao
Journal:  Eye (Lond)       Date:  2011-03-18       Impact factor: 3.775

3.  Vitreous Substitutes.

Authors:  William Joseph Foster
Journal:  Expert Rev Ophthalmol       Date:  2008-04

Review 4.  A tissue-engineered approach towards retinal repair: scaffolds for cell transplantation to the subretinal space.

Authors:  Sara Royce Hynes; Erin B Lavik
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-19       Impact factor: 3.117

5.  Evaluation of 5-fluorouracil released from a foldable capsular vitreous body in vitro and in vivo.

Authors:  Haihua Zheng; Zhimin Wang; Peijuan Wang; Yaqin Liu; Zhaoxin Jiang; Qianying Gao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-11-27       Impact factor: 3.117

6.  A cross-linked hyaluronic acid hydrogel (Healaflow(®)) as a novel vitreous substitute.

Authors:  Henrik Barth; Sven Crafoord; Sten Andréasson; Fredrik Ghosh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-01-08       Impact factor: 3.117

7.  A new model for in vitro testing of vitreous substitute candidates.

Authors:  Henrik Barth; Sven Crafoord; Timothy M O'Shea; Christopher D Pritchard; Robert Langer; Fredrik Ghosh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-25       Impact factor: 3.117

8.  Tamponade efficiency of perfluorohexyloctane and silicone oil solutions in a model eye chamber.

Authors:  C Wetterqvist; D Wong; R Williams; T Stappler; E Herbert; S Freeburn
Journal:  Br J Ophthalmol       Date:  2004-05       Impact factor: 4.638

9.  Engineering retinal progenitor cell and scrollable poly(glycerol-sebacate) composites for expansion and subretinal transplantation.

Authors:  Stephen Redenti; William L Neeley; Santiago Rompani; Sunita Saigal; Jing Yang; Henry Klassen; Robert Langer; Michael J Young
Journal:  Biomaterials       Date:  2009-04-09       Impact factor: 12.479

10.  Poly(ethylene glycol) hydrogels with adaptable mechanical and degradation properties for use in biomedical applications.

Authors:  Matthew Parlato; Sarah Reichert; Neal Barney; William L Murphy
Journal:  Macromol Biosci       Date:  2014-01-25       Impact factor: 4.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.